Alessandro Di Federico, Research Fellow at Memorial Sloan Kettering Cancer Center, shared on LinkedIn:
“Thanks to the International Association for the Study of Lung Cancer for highlighting our work on drug-orphan BRAF class II and III alterations in lung cancer.
We are still working on this study, with the aim of providing the most comprehensive characterization of these tumors to date and, hopefully, open more doors to future treatments for patients.”
This also can be interesting:
LIGHT-NING: Real-World Nivolumab Plus Ipilimumab Shows Durable Outcomes in Metastatic NSCLC
